The US approved an Alzheimer’s drug. Seven patients subsequently died.
Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
A further presentation during the same symposium at AD/PD 2025 focused on how MRI methods could be accelerated to improve ...
BioPharma Dive4d
Leqembi’s EU review drags on; Sanofi gets a new development head
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...
Yahoo Finance2d
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
An updated prescribing label could help increase the uptake of Kisunla, with the reduced ARIA risk more in line with Eisai/Biogen’s Leqembi (lecanemab). In other regions, such as Europe ...
The European Commission refers lecanemab decision to Appeal Committee
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer ...
pharmaphorum2d
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...
Mena FN6d
The European Commission Refers Lecanemab Decision To Appeal Committee
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his ...
pharmaphorum4d
Eisai sets Leqembi price in Japan at a discount to US
Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.
The Pharma Letter5d
EC refers lecanemab decision to Appeal Committee
Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing ...